BioCardia (BCDA) AI Stock Analysis

• Market Cap: $12.44M
• Dividend Yield: N/A
• Average Volume (3M): 174.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.11
• Revenue Growth: -99.36%
• EPS Growth: 63.06%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 5,503,802
• 10 Day Avg. Volume: 416,292
• 30 Day Avg. Volume: 174,520
• PEG Ratio: -0.06
• Price to Book (P/B): -7.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.48
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 26.37
• Enterprise Value/Gross Profit: -54.96
• Enterprise Value/Ebitda: -0.40
• 1Y Price Target: $6.00
• Price Target Upside: 163.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: $2.50 ▲(9.65%Upside)

BioCardia's overall stock score is influenced by significant financial challenges and a weak valuation. However, the progress in clinical trials and recent corporate events provide some optimism for future growth. The technical indicators are neutral, reflecting a balanced market sentiment but no strong momentum.

Positive Factors

Financial Performance

Biocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.

Financial Stability

The company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.

New Product

Morph DNA Introducer now commercially available, providing new revenue stream.

Negative Factors

Clinical Trial

DSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.

Regulatory Challenges

PMDA willing to review CardiAMP HF data ahead of submission for approval in Japan.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc. (BCDA) is a clinical-stage regenerative medicine company focused on the development of innovative therapeutics designed to stimulate the body's natural ability to heal itself. The company operates primarily in the biotechnology and healthcare sectors, specializing in the development of novel therapeutics for cardiovascular diseases. BioCardia's core product candidates include CardiAMP and CardiALLO cell therapies, which are intended to treat heart failure and other cardiac conditions. These therapies leverage the company's proprietary Helix biotherapeutic delivery system to deliver cells directly to the heart muscle.

How the Company Makes Money

BioCardia generates revenue through a combination of product sales, licensing agreements, and collaborations. The company primarily aims to commercialize its cell therapy candidates, such as CardiAMP and CardiALLO, upon successful completion of clinical trials and regulatory approvals. BioCardia also earns revenue from licensing its proprietary biotherapeutic delivery platform to other companies in the biopharmaceutical sector. Additionally, the company engages in partnerships and collaborations that provide research funding and milestone-based payments, further contributing to its revenue streams. These partnerships often align with BioCardia's strategic goals in advancing regenerative medicine solutions for cardiovascular diseases.

BioCardia Financial Statement Overview

Summary

BioCardia's financial performance is weak, with consistently negative EBIT and net income margins, high debt-to-equity ratio, and reliance on external financing. Despite some improvement in cash reserves, the overall outlook remains challenging.

Income Statement

BioCardia's income statement indicates significant challenges with profitability, as evidenced by consistently negative EBIT and net income margins. Revenue has been highly volatile, with a dramatic decrease over the years and a substantial dip in gross profit. This volatility, coupled with negative margins, suggests financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet reveals a weak equity position with negative stockholders' equity in previous years, which has slightly improved to a positive figure recently. The debt-to-equity ratio is relatively high, indicating potential leverage risks. Despite an increase in cash and short-term investments, overall asset growth has been stagnant, raising concerns about long-term financial health.

Cash Flow

The cash flow statement shows consistently negative free cash flow, although there has been some improvement in operating cash flow relative to net income. High reliance on financing activities to manage cash flow needs highlights challenges in generating sufficient operating cash. This reliance on external financing can be risky if not managed carefully.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.00K	477.00K	1.35M	1.01M	145.00K
Gross Profit	-4.33M	-7.25M	-10.55M	375.00K	141.00K
EBITDA	-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
Net Income	-7.95M	-11.57M	-11.91M	-12.62M	-15.00M
Balance Sheet
Total Assets	3.72M	2.99M	9.79M	15.72M	23.42M
Cash, Cash Equivalents and Short-Term Investments	2.37M	1.10M	7.36M	12.87M	21.41M
Total Debt	951.00K	1.31M	1.63M	1.87M	614.00K
Total Liabilities	2.89M	4.59M	4.90M	5.34M	4.25M
Stockholders Equity	837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow
Free Cash Flow	-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
Operating Cash Flow	-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
Investing Cash Flow	-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
Financing Cash Flow	9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Negative. The current price of 2.28 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.25, and below the 200-day MA of 2.33, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 49.98 is Neutral, neither overbought nor oversold. The STOCH value of 50.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$16.23B	5.53	-7.44%	3.84%	11.55%	-28.15%
BCDA	53 Neutral	$12.44M	―	-737.89%	―	-99.36%	63.06%
BRTX	48 Neutral	$11.93M	―	-117.16%	―	175.03%	55.34%
HCWB	46 Neutral	$11.56M	―	-9999.00%	―	-63.20%	15.71%
SNSE	40 Underperform	$10.34M	―	-64.18%	―	―	1.00%
CTXR	38 Underperform	$16.65M	―	-60.06%	―	―	8.99%
LPTX	31 Underperform	$14.50M	―	-202.81%	―	―	64.01%

BioCardia Corporate Events

BioCardia Launches Phase 3 CardiAMP HF II Trial

On July 16, 2025, BioCardia announced that Henry Ford Health in Detroit, Michigan, has begun enrolling patients with ischemic heart failure in the company’s pivotal Phase 3 CardiAMP HF II trial. This trial is a confirmatory study of autologous bone marrow-derived mononuclear cell therapy, aiming to promote microvascular repair and improve heart function in patients with ischemic heart failure. The trial seeks to confirm the safety and efficacy results observed in previous studies and could potentially enhance treatment options for patients with heart failure.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Completes Private Placement Agreement

On June 30, 2025, BioCardia, Inc. completed a private placement agreement with institutional buyers and company insiders, raising approximately $570,000. The funds will be used for general corporate purposes, and the company plans to register the shares for resale with the SEC by July 10, 2025.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Secures Patent for Innovative Catheter System

On June 25, 2025, BioCardia announced the granting of US Patent No. 12,311,127 for its ‘Radial and Trans-endocardial Delivery Catheter’ by the United States Patent Office. This patent covers BioCardia’s minimally invasive catheter systems designed to deliver biologic therapies to the heart, enhancing treatment precision and safety. The Helix catheter system, integral to the company’s CardiAMP Cell Therapy program, is expected to significantly impact the treatment of ischemic cardiomyopathies and heart failure, potentially improving patient outcomes and facilitating the transition from development to commercialization.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Advances Phase 3 CardiAMP HF II Trial

On May 6, 2025, BioCardia, Inc. announced that the University of Wisconsin in Madison has begun enrolling patients with ischemic heart failure in the ongoing pivotal Phase 3 CardiAMP HF II trial. This study is evaluating the CardiAMP cell therapy product for treating patients with ischemic heart failure with reduced ejection fraction and elevated cardiac stress markers. The trial aims to confirm the safety and efficacy of the therapy, which has shown promising results in improving survival and quality of life for heart failure patients. The study’s advancements include refined treatment dose definitions and improvements to the Helix system, potentially expanding patient eligibility and treatment effectiveness.

BioCardia Enrolls First Patient in Phase III Trial

On May 1, 2025, BioCardia announced the enrollment of the first patient in the Phase III CardiAMP HF II clinical trial at BayCare Morton Plant Hospital in Florida. This trial aims to confirm the safety and efficacy of its lead autologous cell therapy for heart failure, potentially impacting regulatory approvals and adoption. The trial builds on previous promising results, with advancements in patient eligibility and delivery systems, and is supported by the Maryland Stem Cell Research Fund and CMS reimbursement.